Wegovy Market Shift: Hims & Hers Shares Jump After Novo Nordisk Drops Patent Case Over Compounded Weight-Loss Drugs

Shares in Hims & Hers Health rose after Novo Nordisk withdrew a patent lawsuit related to combination drugs for weight loss. The controversy began when Novo Nordisk accused the telehealth company of selling mixed versions of its GLP-1 drugs, including Vegovy and Ozempic. The companies later reached a new agreement that allows Hims & Hers to offer Novo's FDA-approved drugs through its platform. Hims & Hers will stop advertising GLP-1 combination treatments because it is the p

13 hours ago2 min read

Hims and Novo Nordisk Resolve Dispute to Sell Obesity Drugs Together, Expanding GLP-1 Market Access

Novo Nordisk and His & Hers Health have formed a new alliance to sell obesity medications after resolving their legal disputes. The program provides patients with access to Novo Nordisk's well-known GLP-1 weight loss medications, such as Vegovy and Ozempic, via Hims' telemedicine platform. Due to patent and safety issues, Novo Nordisk sued Himes for marketing mixed formulations of semaglutide, the active component in these medications. As part of the new agreement, Himes will

3 days ago3 min read

FDA Approves Leucovorin for Rare Genetic Disorder but Declines Use for Autism Treatment

Recently, FDA or the U.S. Food and Drug Administration has accepted the medicine Leucovorin for curing of genetic disease linked to folate metabolism. This approval gives new hope for patients who struggle with serious neurological and developmental signs due to the circumstance. However, the FDA declined to approve leucovorin as a remedy for Autism Spectrum Disorder. Regulators stated modern-day scientific proof does now not really prove that the drug is secure and powerful

5 days ago2 min read